After losing £10.8 million last year, life sciences specialist PuriCore says first-quarter revenues have soared.

The Stafford-based company, which develops proprietary products to kill contagious pathogens whose applications include food safety, medical device disinfection and wound therapy, saw its deficit rise 20 per cent in 2007 on revenue up 17 per cent to £9.3 million. During the year, fully listed PuriCore’s Sterilox Endoscopy food safety product received ‘10k clearance’ from the US Food and Drugs Administration and established new US patents for its wound therapy treatment.

The company, which ended the year with nearly £8 million cash, has experienced a sharp acceleration in some areas. Chief executive Greg Bosch says first quarter revenues were 89 per cent up on a year earlier at £4.6 million, with food safety product sales ahead by 128 per cent to £2.15 million and YUK endoscopy sales 68 per cent forward to £2.35 million.

Bosch says he expects revenue growth of this order to continue throughout this year. At 25.75p, down from 83p in 2006 but up from 16.75p last month, the shares value he company at £39.37 million.

Growth Company Investor subscribers have full access to all our AIM and small-cap share recommendations. To subscribe today with a half-price offer, and gain immediate access to all the recommendations, click here.

Puricore	LSE	£17.06m	7.88p	0.00p
Click here for interactive charting
Other company articles:
PuriCore seeks £10m			31/07/2008
Acceleration at PuriCore			29/04/2008